MK-2206
| Code | Size | Price |
|---|
| TAR-T62609-5mg | 5mg | £1,167.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T62609-50mg | 50mg | £2,307.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T62609-100mg | 100mg | £2,898.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Documents
Further Information
Bioactivity:
MK-2206 is an orally active, highly selective, metabotropic Akt inhibitor that acts on Akt1 (IC50: 8 nM), Akt2 (IC50: 12 nM) and Akt3 (IC50: 65 nM). Many breast cancer cell lines, PIK3CA mutants and PTEN-losing cell lines are sensitive to MK-2206, which has anti-cancer effects.
CAS:
1032349-77-1
Molecular Weight:
443.94
Purity:
0.98
SMILES:
Cl.NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1
References
Liang J, Zhao G, Bian Y, et al.HNF4G increases cisplatin resistance in lung adenocarcinoma via the MAPK6/Akt pathway.PeerJ.2023, 11: e14996.
Sun R, Ge W, Zhu Y, et al.Proteomic Dynamics of Breast Cancer Cell Lines Identifies Potential Therapeutic Protein Targets.Molecular & Cellular Proteomics.2023: 100602.
Xie X, Zhang W, Zhou X, et al.Low doses of IFN-? maintain self-renewal of leukemia stem cells in acute myeloid leukemia.Oncogene.2023: 1-13.
Yang N, Fan Z, Sun S, et al.Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation.European Journal of Medicinal Chemistry.2023: 115857.